Abstract:Atomic structures of human γ-secretase bound to inhibitors and the modulator E2012Differential recognition of clinical candidates Semagacestat and AvagacestatDifferential recognition of transition state analog (TSA) L685,458 and non-TSAIdentification of the allosteric binding site of the γ-secretase modulator E2012Development of γ-secretase inhibitors (GSIs) and modulators (GSMs) represents an attractive therapeutic opportunity for Alzheimer's disease (AD) and cancers. However, how these GSIs and GSMs target γ-secretase has remained largely unknown. Here, we report the cryoelectron microscopy (cryo-EM) structures of human γ-secretase bound individually to two GSI clinical candidates, Semagacestat and Avagacestat, a transition state analog GSI L685,458, and a classic GSM E2012, at overall resolutions of 2.6–3.1 Å. Remarkably, each of the GSIs occupies the same general location on presenilin 1 (PS1) that accommodates the β strand from amyloid precursor protein or Notch, interfering with substrate recruitment. L685,458 directly coordinates the two catalytic aspartate residues of PS1. E2012 binds to an allosteric site of γ-secretase on the extracellular side, potentially explaining its modulating activity. Structural analysis reveals a set of shared themes and variations for inhibitor and modulator recognition that will guide development of the next-generation substrate-selective inhibitors.<ol class="links-for-figure"><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S0092867420316214-fx1_lrg.jpg">Download : Download high-res image (253KB)</a></li><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S0092867420316214-fx1.jpg">Download : Download full-size image</a></li></ol>

Structural basis of γ-secretase inhibition and modulation by small molecule drugs

Structural basis of -secretase inhibition and modulation by small molecule drugs

Understanding the Modulatory Role of E2012 on the γ-Secretase-Substrate Interaction

Enzyme–substrate interface targeting by imidazole‐based γ‐secretase modulators activates γ‐secretase and stabilizes its interaction with APP

Structural Analysis of the Simultaneous Activation and Inhibition of γ-Secretase Activity in the Development of Drugs for Alzheimer's Disease

Modulation of gamma-secretase specificity using small molecule allosteric inhibitors.

An atomic structure of human γ-secretase

γ-Secretase Modulatory Proteins: The Guiding Hand Behind the Running Scissors

Molecular basis for isoform-selective inhibition of presenilin-1 by MRK-560

γ-Secretase Studied by Atomistic Molecular Dynamics Simulations: Global Dynamics, Enzyme Activation, Water Distribution and Lipid Binding

Three-dimensional structure of human γ-secretase

Recent Advances of γ-secretase：γ-secretase Activating Protein

Structural Basis of Human Γ-Secretase Assembly.

Gamma Secretase as an Important Drug Target for Management of Alzheimer's Disease: A Comprehensive Review

Recognition of the Amyloid Precursor Protein by Human Gamma-Secretase

Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species.

The Gamma-Secretase Complex: from Structure to Function

Conformational Changes and Unfolding of β-Amyloid Substrates in the Active Site of γ-Secretase

Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer's Disease

Spirocyclic Sulfamides As Β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer's Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies to Identify Centrally Efficacious Inhibitors.

Extracellular interface between APP and Nicastrin regulates Aβ length and response to γ‐secretase modulators